Opportunity Information: Apply for CDC RFA DP14 1407
Apply for CDC RFA DP14 1407
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "Enhancing Cancer Genomic Best Practices through Education, Surveillance, and Policy" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.283 Centers for Disease Control and PreventionInvestigations and Technical Assistance.
- This funding opportunity was created on May 9, 2014 and posted on May 2, 2014.
- Applicants must submit their applications by Jun 17, 2014 Dates 1. Letter of Intent (LOI) Deadline May 19, 2014 2. Application Deadline June 17, 2014, 1159 p.m. U.S. Eastern Standard Time, on www.grants.gov 3. Informational conference call for potential applicants May 12, 2014 at 200p.m. call number 1 (877) 601 5563 Participant Code 6130030. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $1,500,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $350,000.00 in funding.
- The number of recipients for this funding is limited to 5 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Eligibility Information 1. Eligible Applicants Government Organizations State or their bona fide agents (includes the District of Columbia) Territorial governments or their bona fide agents in the Commonwealth of Puerto Rico and the Virgin Islands. 2. Special Eligibility Requirements All eligible applications will be initially reviewed for completeness by the Procurement and Grants Office (PGO) staff. In addition, eligible applications will be jointly reviewed for responsiveness by National Center for Chronic Disease Prevention and Health Promotion and PGO. Incomplete applications and applications that are non responsive to the eligibility criteria will not advance through the review process. Applicants will be notified the application did not meet eligibility and/or published submission requirements.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The CDC funding opportunity "Enhancing Cancer Genomic Best Practices through Education, Surveillance, and Policy" (Funding Opportunity Number: CDC RFA DP14-1407) is a cooperative agreement designed to help states build or expand programs that put evidence-based cancer genomics into everyday public health practice. The central focus is Hereditary Breast and Ovarian Cancer (HBOC), especially risk related to BRCA1 and BRCA2 mutations, with the option to include work on Lynch syndrome as well. The overall intent is practical and systems-oriented: reduce preventable cancer burden by improving how high-risk individuals are identified, referred, tested, and connected to proven risk-reducing services.
The program is rooted in a clear public health problem. Many people who meet clinical criteria for hereditary cancer risk are not appropriately identified or do not receive recommended genetic counseling and testing, often because of barriers at multiple levels. These barriers can include gaps in provider knowledge and referral practices, limited public awareness, uneven access to genetic services, insurance and coverage challenges, and weak data systems for tracking genetic counseling, testing, and follow-up care. This FOA supports state efforts to tackle those obstacles through coordinated education initiatives, better surveillance and data use, and policy or systems changes that make appropriate care easier to access and sustain.
Funded states are expected to develop, enhance, and evaluate activities in three main areas: education, surveillance, and policy/systems change. Education efforts are intended to improve understanding of hereditary cancer risk and appropriate use of genetic counseling and testing among both the public and healthcare providers. Surveillance activities emphasize measuring and understanding the burden of hereditary cancers and monitoring the use of genetic counseling, genetic testing, and related clinical services. Policy and systems work aims to improve access to services for high-risk individuals, including addressing coverage and reimbursement issues and strengthening referral pathways and clinical processes. A key theme is evaluation: states should not only implement activities, but also assess what works and demonstrate progress toward measurable outcomes.
Collaboration is a core expectation of this opportunity. Applicants are encouraged to build strong partnerships internally within state health systems (for example, with the state cancer registry and comprehensive cancer control programs) and externally with organizations that can extend reach and expertise (such as academic medical centers, nonprofit organizations, and clinical genetics providers or sites). The idea is to connect public health infrastructure, clinical practice, and community partners so that evidence-based recommendations translate into real-world improvements in care delivery.
The opportunity highlights the clinical justification for focusing on BRCA-related HBOC. Women with BRCA1/2 mutations have substantially higher lifetime risks of breast and ovarian cancer, cited here as up to 57 percent for breast cancer and up to 40 percent for ovarian cancer. For women whose personal or family history suggests a BRCA mutation, genetic counseling and testing can clarify risk and guide care. For those who test positive, the FOA points to interventions such as chemoprevention, enhanced surveillance, and risk-reducing surgeries (prophylactic mastectomy and oophorectomy), which can significantly reduce cancer incidence (up to 95 percent reduction for breast cancer incidence and up to 80 percent reduction for ovarian cancer incidence, as stated in the announcement). The FOA also emphasizes that major guideline bodies, including the U.S. Preventive Services Task Force (USPSTF) and the National Comprehensive Cancer Network (NCCN), provide evidence-based recommendations supporting appropriate genetic counseling and testing for hereditary breast and ovarian cancer.
Lynch syndrome is included as an additional area states may address. The announcement notes that people with Lynch syndrome face elevated risks for colorectal cancer and other cancers such as gastric, endometrial, and ovarian cancers. It references the EGAPP Working Group finding sufficient evidence to recommend offering Lynch syndrome genetic testing to individuals with newly diagnosed colorectal cancer, with the goal of reducing morbidity and mortality in relatives through identification and preventive action. This signals that states can broaden hereditary cancer work beyond BRCA when it aligns with evidence-based practice and program capacity.
In terms of funding structure, this is a discretionary cooperative agreement in the health category (CFDA 93.283). CDC anticipated making about five awards, with an estimated total funding amount of $1,500,000. Individual awards were expected to range from $150,000 (floor) to $350,000 (ceiling). There was no cost sharing or matching requirement. Eligibility was limited to government organizations, specifically states (including the District of Columbia) and territorial governments or their bona fide agents in Puerto Rico and the U.S. Virgin Islands, with applications subject to completeness and responsiveness screening before peer review.
Key dates in the original posting included a letter of intent deadline of May 19, 2014, and an application deadline of June 17, 2014 (11:59 p.m. Eastern) submitted through Grants.gov. The CDC also offered an informational conference call for potential applicants on May 12, 2014. While the listing is archived (archive date July 17, 2014), the content lays out a model for how CDC sought to strengthen state capacity to apply genomic best practices to cancer prevention and control through coordinated education, improved tracking and surveillance, and policy and systems improvements that expand access to high-value genetic services for high-risk populations.
FAQs: CDC RFA DP14-1407 - Enhancing Cancer Genomic Best Practices through Education, Surveillance, and Policy
What is this funding opportunity?
This is a CDC discretionary cooperative agreement called "Enhancing Cancer Genomic Best Practices through Education, Surveillance, and Policy" (Funding Opportunity Number: CDC RFA DP14-1407). It is designed to help states build or expand programs that integrate evidence-based cancer genomics into routine public health practice.
What is the main public health focus of the program?
The central focus is Hereditary Breast and Ovarian Cancer (HBOC), particularly hereditary risk related to BRCA1 and BRCA2 mutations. The opportunity also allows states to include work on Lynch syndrome as an additional area.
What is the overall goal CDC is trying to achieve with this cooperative agreement?
The intent is practical and systems-oriented: reduce preventable cancer burden by improving how high-risk individuals are identified, referred, tested, and connected to proven risk-reducing services.
Why does CDC consider this a priority problem?
The opportunity is rooted in the problem that many people who meet clinical criteria for hereditary cancer risk are not appropriately identified or do not receive recommended genetic counseling and testing. CDC highlights multi-level barriers such as provider knowledge and referral gaps, limited public awareness, uneven access to genetic services, insurance and coverage challenges, and weak data systems to track counseling, testing, and follow-up care.
What types of activities are funded under this opportunity?
Funded states are expected to develop, enhance, and evaluate activities in three main areas: education, surveillance, and policy/systems change.
What does "education" mean in the context of this FOA?
Education efforts are intended to improve understanding of hereditary cancer risk and the appropriate use of genetic counseling and testing among both the public and healthcare providers.
What does "surveillance" mean in the context of this FOA?
Surveillance activities emphasize measuring and understanding the burden of hereditary cancers and monitoring the use of genetic counseling, genetic testing, and related clinical services. The FOA also points to the importance of better data use and tracking.
What does "policy/systems change" mean in the context of this FOA?
Policy and systems work aims to improve access to services for high-risk individuals. Examples described in the FOA include addressing coverage and reimbursement issues, strengthening referral pathways, and improving clinical processes that make appropriate care easier to access and sustain.
Is evaluation required?
Yes. A recurring theme in the opportunity is evaluation. States are expected not only to implement activities, but also to assess what works and demonstrate progress toward measurable outcomes.
What kinds of partnerships does CDC expect applicants to build?
Collaboration is a core expectation. Applicants are encouraged to build partnerships within state health systems (for example, with the state cancer registry and comprehensive cancer control programs) and externally with organizations such as academic medical centers, nonprofit organizations, and clinical genetics providers or sites.
Why is the FOA focused on BRCA-related hereditary breast and ovarian cancer?
The FOA highlights the clinical justification that women with BRCA1/2 mutations have substantially higher lifetime risks of breast and ovarian cancer, cited as up to 57 percent for breast cancer and up to 40 percent for ovarian cancer.
How does genetic counseling and testing fit into the program model?
For women whose personal or family history suggests a BRCA mutation, genetic counseling and testing can clarify risk and guide care. CDC emphasizes improving systems so that appropriate individuals are identified, referred, tested, and connected to evidence-based services.
What risk-reducing interventions are mentioned for individuals who test positive for BRCA mutations?
The FOA references interventions such as chemoprevention, enhanced surveillance, and risk-reducing surgeries (prophylactic mastectomy and oophorectomy). The announcement states these can significantly reduce cancer incidence, citing up to a 95 percent reduction for breast cancer incidence and up to an 80 percent reduction for ovarian cancer incidence.
Which evidence-based guidelines are referenced to support this work?
The FOA notes that major guideline bodies, including the U.S. Preventive Services Task Force (USPSTF) and the National Comprehensive Cancer Network (NCCN), provide evidence-based recommendations supporting appropriate genetic counseling and testing for hereditary breast and ovarian cancer.
Is Lynch syndrome included, and if so, how?
Yes. Lynch syndrome is presented as an additional area that states may address. The FOA notes elevated risks for colorectal cancer and other cancers such as gastric, endometrial, and ovarian cancers.
What specific evidence basis is mentioned for Lynch syndrome activities?
The FOA references the EGAPP Working Group finding sufficient evidence to recommend offering Lynch syndrome genetic testing to individuals with newly diagnosed colorectal cancer, with the aim of reducing morbidity and mortality in relatives through identification and preventive action.
What is the funding mechanism and program category?
This opportunity is a discretionary cooperative agreement in the health category, listed under CFDA 93.283.
How many awards did CDC anticipate making and what was the total funding amount?
CDC anticipated making about five awards, with an estimated total funding amount of $1,500,000.
What was the expected award size for individual recipients?
Individual awards were expected to range from $150,000 (floor) to $350,000 (ceiling).
Was cost sharing or matching required?
No. The FOA states there was no cost sharing or matching requirement.
Who was eligible to apply?
Eligibility was limited to government organizations, specifically states (including the District of Columbia) and territorial governments or their bona fide agents in Puerto Rico and the U.S. Virgin Islands.
Were applications screened before peer review?
Yes. Applications were subject to completeness and responsiveness screening before peer review.
How were applications submitted?
Applications were to be submitted through Grants.gov.
What were the key dates listed in the original posting?
The FOA listed a letter of intent deadline of May 19, 2014, and an application deadline of June 17, 2014 (11:59 p.m. Eastern). It also mentioned an informational conference call for potential applicants on May 12, 2014.
Is this opportunity still open?
The listing is archived, with an archive date of July 17, 2014. The information provided describes the structure and expectations of that archived opportunity.
What is the practical model CDC is promoting through this funding opportunity?
The FOA lays out a model for strengthening state capacity to apply cancer genomic best practices through coordinated education, improved tracking and surveillance, and policy and systems improvements that expand access to high-value genetic services for high-risk populations.
Browse more opportunities from the same agency: Centers for Disease Control and Prevention
Browse more opportunities from the same category: Health
Next opportunity: Small Socially Disadvantaged Producer Grant
Previous opportunity: Enhancing Cancer Registries for Early Case Capture (ECC) of Pediatric and Young Adult Cancer (PYAC) Cases
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA DP14 1407
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA DP14 1407) also looked into and applied for these:
| Funding Opportunity |
|---|
| HIV Vaccine Research and Design (HIVRAD) Program (P01) Apply for PAR 14 206 Funding Number: PAR 14 206 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Protecting and Improving Public Health Globally Building and Strengthening Public Health Impact, Systems, Capacity and Security Apply for CDC RFA GH14 1418 Funding Number: CDC RFA GH14 1418 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Center for Inherited Disease Research (CIDR) High Throughput Sequencing and Genotyping Resource Access (X01) Apply for PAR 14 207 Funding Number: PAR 14 207 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Longitudinal Assessment of Post traumatic Syndromes (U01) Apply for RFA MH 15 110 Funding Number: RFA MH 15 110 Agency: National Institutes of Health Category: Health Funding Amount: $5,000,000 |
| Enhancing situational awareness, surveillance, detection, risk assessment and response activities using a mapping and visualization tool Apply for CDC RFA CK14 1404 Funding Number: CDC RFA CK14 1404 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre Clinical Research (R44) Apply for PAR 14 209 Funding Number: PAR 14 209 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Exploratory Clinical Trials and Clinical Research (R44) Apply for PAR 14 208 Funding Number: PAR 14 208 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Affordable Care Act SHIP and ADRC Options Counseling for Medicare Medicaid Individuals in States with Approved Financial Alignment Models Apply for CMS 1N1 14 001 Funding Number: CMS 1N1 14 001 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $1,000,000 |
| Pharmacogenomics Knowledge Base (R24) Apply for RFA GM 15 002 Funding Number: RFA GM 15 002 Agency: National Institutes of Health Category: Health Funding Amount: $1,600,000 |
| Local Nongovernmental Partnerships for Sustained Country Leadership in Rwanda under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH14 1414 Funding Number: CDC RFA GH14 1414 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| FY14 Minority Youth Violence Prevention Integrating Public Health and Community Policing Approaches Apply for MP YEP 14 001 Funding Number: MP YEP 14 001 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $400,000 |
| NIMHD Social, Behavioral, Health Services, and Policy Research on Minority Health and Health Disparities (R01) Apply for RFA MD 14 004 Funding Number: RFA MD 14 004 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| NIMHD Basic and Applied Biomedical Research on Minority Health and Health Disparities (R01) Apply for RFA MD 14 005 Funding Number: RFA MD 14 005 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| FY14 Youth Empowerment Program II (YEP II) Apply for MP YEP 14 005 Funding Number: MP YEP 14 005 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $500,000 |
| CDCs Collaboration with Academia to Strengthen Public Health Workforce Capacity Apply for CDC RFA OE12 120103CONT14 Funding Number: CDC RFA OE12 120103CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Frontier Community Health Integration Project Technical Assistance, Tracking, and Analysis Apply for HRSA 14 137 Funding Number: HRSA 14 137 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| PPHF 2014 Cancer Prevention and Control Programs for State, Territorial and Tribal Organizations financed in part by 2014 Prevention and Public Health Funds Apply for CDC RFA DP12 1205PPHF14 Funding Number: CDC RFA DP12 1205PPHF14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Reinvestment of Civil Money Penalties to Benefit Nursing Home Residents Apply for CMS 1K1 14 001 Funding Number: CMS 1K1 14 001 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $500,000 |
| Civil Society Capacity Building for Advocacy and Response to the HIV/AIDS Epidemic Among Key Populations in India under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH14 1411 Funding Number: CDC RFA GH14 1411 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $800,000 |
| State Based Perinatal Quality Collaboratives Apply for CDC RFA DP14 1404 Funding Number: CDC RFA DP14 1404 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA DP14 1407", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.